Tine Ottenbourgs

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Metabolic Syndrome

Estrogen Receptor

Cross Sectional

Top Venues

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

This page only lists publications with an associated author ORCID identifier.

Publications

Tine Ottenbourgs, Toon Van Gorp, Frédéric Kridelka, Thaïs Baert, Hannelore Denys, Frédéric Selle, Inge Baas, Anne-Sophie Van Rompuy, Diether Lambrechts, Els Van Nieuwenhuysen
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 34 (4) (2024)
Tine Ottenbourgs, Toon Van Gorp, Frédéric Kridelka, Thaïs Baert, Hannelore Denys, Frédéric Selle, Inge Baas, Anne-Sophie Van Rompuy, Diether Lambrechts, Els Van Nieuwenhuysen
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
Tine Ottenbourgs, Els Van Nieuwenhuysen
Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer-What Can We Learn from Breast Cancer? Cancers 16 (10) (2024)
Tine Ottenbourgs, Toon Van Gorp, Frédéric Kridelka, Thaïs Baert, Hannelore Denys, Frédéric Selle, Inge Baas, Anne-Sophie Van Rompuy, Diether Lambrechts, Els Van Nieuwenhuysen
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 34 (4) (2024)
Tine Ottenbourgs, Toon Van Gorp, Frédéric Kridelka, Thaïs Baert, Hannelore Denys, Frédéric Selle, Inge Baas, Anne-Sophie Van Rompuy, Diether Lambrechts, Els Van Nieuwenhuysen
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 34 (4) (2024)
Tine Ottenbourgs, Els Van Nieuwenhuysen
Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer-What Can We Learn from Breast Cancer? Cancers 16 (10) (2024)